Kymera Therapeutics

Precision Targeting of MYD88 Mutant DLBCL Using the Novel Combination of IRAKIMiD sand BCL2 Inhibition

Read more

Discovery and characterization of potent degraders of IRAK4 and IMiD substrates for oncology indications

Read more

Discovery of IRAKIMiDs: Dual-Mechanism Degraders Targeting IRAK4 and IMiDSubstrates for Oncology

Read more

Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications

Read more

Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Read more

16th Annual International Conference on Malignant Lymphoma (ICML) Virtual Meeting, June 18 – 22, 2021

Read more

American Association of Cancer Research (AACR) 2021 Annual Meeting, April 10-15, 2021

Read more

62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition, December 5-8, 2020

Read more

62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition, December 5-8, 2020

Read more

IRAKIMiDs: A Single Small Molecule Approach to Developing Dual-Function Degraders for B Cell Lymphoma with Multiple Drivers

Read more